Literature DB >> 31104565

Incident Left Ventricular Hypertrophy in Masked Hypertension.

Cesare Cuspidi1,2, Rita Facchetti1, Fosca Quarti-Trevano1, Carla Sala3, Marijana Tadic4, Guido Grassi1, Giuseppe Mancia1.   

Abstract

In the PAMELA study (Pressioni Arteriose Monitorate e Loro Associazioni), clinical variables, an echocardiogram, as well as office and ambulatory blood pressure (ABP) were simultaneously measured at baseline and after a 10-year follow-up. The study design allowed us to assess the value of masked hypertension (MH) as a predictor of new-onset left ventricular hypertrophy (LVH). The present analysis included 803 participants without LVH at baseline (left ventricular mass index <115 g/m2 in men and <100 g/m2 in women). Based on office and 24-hour mean ABP values, subjects were divided into 3 groups: normal subjects (normotensive, office blood pressure [BP] <140/90 mm Hg and 24-hour mean ABP <130/80 mm Hg), MH (office BP, normal, and 24-hour mean ABP, elevated), and sustained hypertension (office and 24-hour BP, both elevated). At entry, 57 of 803 subjects fulfilled diagnostic criteria for MH (7.1%); 182 participants developed LVH (22.6%). Compared with subjects with normal in-office and out-of-office BP, the risk of new-onset LVH was greater in MH (odds ratio, 2.22; CI, 1.11-4.46, P=0.0250) after adjustment for potential confounders. This was also the case for the absolute increase of left ventricular mass index. Our study provides a new piece of evidence that MH, identified by office and ABP values, is associated with an increased risk of new-onset LVH. Moreover, our findings convey the notion that office BP may inaccurately estimate the risk of incident LVH in the general population.

Entities:  

Keywords:  blood pressure; follow-up studies; humans; masked hypertension; risk

Mesh:

Year:  2019        PMID: 31104565     DOI: 10.1161/HYPERTENSIONAHA.119.12887

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Identifying a metabolomics profile associated with masked hypertension in two independent cohorts: Data from the African-PREDICT and SABPA studies.

Authors:  Michél Strauss-Kruger; Ruan Kruger; Esmé Jansen Van Vuren; Adriaan Jacobs; Roan Louw; Carina Mels
Journal:  Hypertens Res       Date:  2022-09-02       Impact factor: 5.528

2.  Left ventricular mass and incident hypertension: Missing pieces in the puzzle.

Authors:  Cesare Cuspidi; Marijana Tadic; Guido Grassi
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-01       Impact factor: 3.738

3.  Left ventricular hypertrophy in isolated and dual masked hypertension.

Authors:  Cesare Cuspidi; Rita Facchetti; Fosca Quarti-Trevano; Raffaella Dell'Oro; Marijana Tadic; Guido Grassi; Giuseppe Mancia
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-19       Impact factor: 3.738

4.  Comparison of the association of masked hypertension defined by the 2017 ACC/AHA BP guideline versus the JNC7 guideline with left ventricular hypertrophy.

Authors:  Bharat Poudel; Anthony J Viera; Daichi Shimbo; Joseph E Schwartz; James M Shikany; Swati Sakhuja; Donald M Lloyd-Jones; Paul Muntner; Yuichiro Yano
Journal:  J Hypertens       Date:  2022-07-05       Impact factor: 4.776

5.  Relationship Between Masked Hypertension Measured by Ambulatory Blood Pressure Monitoring and Left Ventricular Global Longitudinal Strain: A Retrospective Study.

Authors:  Ming Fu; Xiangming Hu; Shuo Sun; Shixin Yi; Ying Zhang; Yingqing Feng; Yingling Zhou; Qingshan Geng; Haojian Dong
Journal:  Int J Gen Med       Date:  2021-05-25

6.  Prevalences and associated factors of electrocardiographic abnormalities in Chinese adults: a cross-sectional study.

Authors:  Liping Yu; Xiaojun Ye; Zhaojun Yang; Wenying Yang; Bo Zhang
Journal:  BMC Cardiovasc Disord       Date:  2020-09-11       Impact factor: 2.298

7.  Association of free androgen index and sex hormone-binding globulin and left ventricular hypertrophy in postmenopausal hypertensive women.

Authors:  Chen Jianshu; Wang Qiongying; Pei Ying; Li Ningyin; Han Junchen; Yu Jing
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-09       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.